Clonidine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Clonidine: From Its US-Marketed Use to Faciodigitogenital Syndrome
One-Sentence Summary
Clonidine is a centrally acting alpha-2 adrenergic agonist that is currently marketed in the US as injection, tablet, and patch products. The TxGNN model predicts it may be effective for faciodigitogenital syndrome, a rare developmental syndrome. There are 0 clinical trials and 0 publications supporting this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Faciodigitogenital syndrome |
| TxGNN Prediction Score | 99.9993% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Clonidine is known as an alpha-2 adrenergic agonist. This class lowers noradrenergic tone and is used for conditions involving arousal, impulsivity, and sympathetic overactivity.
The review of this prediction found no plausible mechanistic link between alpha-2 agonism and faciodigitogenital syndrome, which is a rare developmental syndrome. The similarity between the original and predicted indications has not been assessed. The very high model score is therefore not backed by any biological rationale, clinical study, or publication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The Evidence Pack lists 20 authorizations in total. The main ones are below. Approved indication text is not provided for any of them.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA200300 | Clonidine Hydrochloride | Injection, solution | Hikma Pharmaceuticals USA Inc. |
| ANDA070974 | Clonidine Hydrochloride | Tablet | NuCare Pharmaceuticals, Inc. |
| ANDA202297 | Clonidine Hydrochloride | Tablet | Bryant Ranch Prepack |
| ANDA070925 | Clonidine Hydrochloride | Tablet | Northwind Health Company, LLC |
Other marketed forms include extended-release tablets, patches, and extended-release patches.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has only a model score, with no clinical trials, no literature, and no plausible mechanism. It cannot support any development decision.
To proceed, the following is needed:
- Mechanism of action data (MOA) and a documented rationale linking alpha-2 agonism to this syndrome
- FDA package insert warnings and contraindications (a blocking gap for safety screening)
- Approved indication text for the US authorizations
- Any preclinical or clinical signal in faciodigitogenital syndrome
Note: Other predictions in the same Evidence Pack have much stronger support. Tourette syndrome (TxGNN rank 5) is rated L1 with a “Proceed with Guardrails” recommendation. It has a completed Phase 4 trial and a randomized, double-blind, placebo-controlled trial of the clonidine patch. Manic bipolar disorder and migraine disorder are rated L3 and could be reviewed as research questions.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.